NASDAQ:SVA - Sinovac Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.47 0.00 (0.00 %) (As of 04/8/2019)Previous Close$6.47Today's Range$6.47 - $6.4752-Week Range$5.73 - $8.75VolumeN/AAverage VolumeN/AMarket Capitalization$370.60 millionP/E RatioN/ADividend YieldN/ABeta0.33 ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China. Receive SVA News and Ratings via Email Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVA Previous Symbol CUSIPN/A CIK1084201 Webhttp://www.sinovac.com/ Phone86-10-5693-1800Debt Debt-to-Equity Ratio0.04 Current Ratio4.88 Quick Ratio4.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$229.65 million Price / Sales1.61 Cash Flow$0.4563 per share Price / Cash Flow14.18 Book Value$5.10 per share Price / Book1.27Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees644 Outstanding Shares57,280,000Market Cap$370.60 million Next Earnings Date7/24/2019 (Estimated) OptionableOptionable Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions What is Sinovac Biotech's stock symbol? Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA." When is Sinovac Biotech's next earnings date? Sinovac Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Sinovac Biotech. Has Sinovac Biotech been receiving favorable news coverage? News headlines about SVA stock have been trending negative on Saturday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sinovac Biotech earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Sinovac Biotech's key competitors? Some companies that are related to Sinovac Biotech include Innoviva (INVA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Cambrex (CBM), Gossamer Bio (GOSS), Endo International (ENDP), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Opko Health (OPK), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Epizyme (EPZM), Eidos Therapeutics (EIDX) and Theravance Biopharma (TBPH). What other stocks do shareholders of Sinovac Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sinovac Biotech investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Prospect Capital (PSEC), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Zynerba Pharmaceuticals (ZYNE), Pfizer (PFE) and Fate Therapeutics (FATE). Who are Sinovac Biotech's key executives? Sinovac Biotech's management team includes the folowing people: Wei Dong Yin, Chairman, President, CEO & SecretaryNan Wang, Chief Financial Officer & VP-Business DevelopmentQiang Gao, Vice President-Research & DevelopmentXiao Mei Yin, Vice President-Sales & MarketingHelen G. Yang, Investor Relations Contact Who are Sinovac Biotech's major shareholders? Sinovac Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.15%), Ramsey Quantitative Systems (0.04%) and Eqis Capital Management Inc. (0.04%). View Institutional Ownership Trends for Sinovac Biotech. Which major investors are selling Sinovac Biotech stock? SVA stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Sinovac Biotech. Which major investors are buying Sinovac Biotech stock? SVA stock was purchased by a variety of institutional investors in the last quarter, including Ramsey Quantitative Systems. View Insider Buying and Selling for Sinovac Biotech. How do I buy shares of Sinovac Biotech? Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sinovac Biotech's stock price today? One share of SVA stock can currently be purchased for approximately $6.47. How big of a company is Sinovac Biotech? Sinovac Biotech has a market capitalization of $370.60 million and generates $229.65 million in revenue each year. Sinovac Biotech employs 644 workers across the globe. What is Sinovac Biotech's official website? The official website for Sinovac Biotech is http://www.sinovac.com/. How can I contact Sinovac Biotech? Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 102200. The biopharmaceutical company can be reached via phone at 86-10-5693-1800 or via email at [email protected] MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 206 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 398MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: Cost of Capital Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.